Dr. Reddy’s moves first in Canada’s generic semaglutide market. Can access improve?
GLP-1 demand is booming, but access remains uneven. Dr. Reddy’s Canada launch tests whether generics can change semaglutide economics.
What Transpire Bio’s Trelegy ANDA reveals about the next wave of inhaler competition
Trelegy is a blockbuster, but complex inhaler generics are closing in. Transpire Bio’s FDA filing could test GSK’s respiratory moat.
How Apotex’s generic Infuvite pediatric approval could shift the sterile injectable multivitamin market
Pediatric nutrition needs reliable sterile supply. Apotex’s Infuvite generic approval tests whether complex generics can ease that gap.
Can Apotex crack the complex generic code for semaglutide before the glucagon-like peptide-1 market resets?
Apotex won first tentative U.S. approval for generic semaglutide. Read what it could mean for glucagon-like peptide-1 access, pricing, and competition.
DifGen Pharmaceuticals expands complex generics footprint with fluorometholone ophthalmic suspension approval
DifGen Pharmaceuticals secures rare FDA approval for fluorometholone ophthalmic suspension. Find out why this complex generic matters for ophthalmology markets.